XML 18 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash Flows from Operating Activities:    
Net income $ 20,570 $ 28,737
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation expense, intangible asset and other amortization 3,009 3,436
Stock-based compensation 6,658 6,433
Excess tax benefits from stock-based compensation (164) (1,328)
Amortization of deferred commissions 1,365 5,339
Payments of deferred commissions (921) (2,040)
Equity in earnings of equity method investments (201) (669)
Realized gain on sale of equity method investment (2,883) 0
Realized and unrealized losses (gains) on trading securities, net 260 (609)
Sales (purchases) of trading securities, net 11,122 8,131
Deferred taxes, net 7,190 636
Changes in operating assets and liabilities:    
Accounts receivable, net and other assets 576 4,665
Accrued compensation and benefits, accounts payable, accrued liabilities and other liabilities (25,430) (15,104)
Net cash provided by operating activities 51,945 1,554
Cash Flows from Investing Activities:    
Capital expenditures (1,093) (2,978)
Proceeds from sale of equity method investment 8,621 0
Asset acquisitions and purchases of other investments (759) (1,601)
Cash acquired in business combination 0 89
Purchases of available-for-sale securities (121) (111)
Net cash provided by (used in) investing activities 6,751 (4,601)
Cash Flows from Financing Activities:    
Dividends paid (7,638) (8,167)
Repurchases of common shares (61,809) (28,000)
Proceeds from exercise of stock options 400 61
Taxes paid related to net share settlement of restricted stock units (1,332) (4,841)
Excess tax benefits from stock-based compensation 164 1,328
Contributions of noncontrolling interests, net 1,537 34,237
Net cash provided by (used in) financing activities 91,590 (4,551)
Net increase (decrease) in cash and cash equivalents 150,286 (7,598)
Cash and cash equivalents, beginning of period 97,384 203,304
Cash and Cash Equivalents, End of Period 247,670 195,706
Non-Cash Investing Activities:    
Change in accrual for capital expenditures 45 (465)
Transfer from Investments 0 4,800
Non-Cash Financing Activities:    
Decrease to noncontrolling interest due to deconsolidation of consolidated sponsored investment products (52,874) (1,569)
Dividends payable 3,473 4,048
Consolidated Sponsored Investment Products [Member]    
Adjustments to reconcile net income to net cash provided by operating activities:    
Realized and unrealized losses (gains) on trading securities, net (4,218) 2,315
Sales (purchases) of trading securities, net 100,436 (39,993)
(Purchases) sales of securities sold short by consolidated sponsored investment products, net (4,455) 2,040
Changes in operating assets and liabilities:    
Cash pledged or on deposit of consolidated sponsored investment products 9,582 (3,489)
Other assets of consolidated sponsored investment products (358) (1,855)
Liabilities of consolidated sponsored investment products 187 4,909
Cash Flows from Investing Activities:    
Change in cash and cash equivalents of consolidated sponsored investment products due to deconsolidation 103 0
Cash Flows from Financing Activities:    
Borrowings of proceeds from short sales by consolidated sponsored investment products 0 831
Payments on borrowings by consolidated sponsored investment products (3,415)
Consolidated Investment Product [Member]    
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization of discount on notes payable of consolidated investment product 3,719 0
Realized and unrealized losses (gains) on trading securities, net (2,146) 0
Sales (purchases) of trading securities, net (71,943) 0
Changes in operating assets and liabilities:    
Other assets of consolidated sponsored investment products (227) 0
Liabilities of consolidated investment product, net 217 0
Cash Flows from Financing Activities:    
Repayment of debt of consolidated investment product (152,597) 0
Proceeds from issuance of notes payable by consolidated investment product $ 316,280 $ 0